Veniti, which focuses on the treatment of venous disease, has inked a distribution deal with its investor, Boston Scientific. The devicemaker will distribute the former’s Vici Venous Stent under a limited global distribution agreement.
The companies did not disclose further details on the agreement.
Boston Sci took part in Veniti’s $25 million series D round in September 2016. Veniti pegged the funds to wrap up its 200-patient trial, run under an investigational device exemption from the FDA, of the Vici stent. The company raised $17 million in series C financing a year prior.
"The VICI VENOUS STENT is widely recognized as state-of-the-art technology for venous stents and physicians routinely praise the product for its performance qualities. We are extremely pleased to be partnering with a global industry leader like Boston Scientific to advance the VICI VENOUS STENT in the marketplace," said Veniti CEO Jeff Elkins, in a statement. "Boston Scientific's market leadership and reach will provide more physicians treating patients suffering from venous outflow obstruction around the world greater access to leading-edge technology."
The most common form of venous obstructive disease is deep-vein thrombosis, which affects as many as 900,000 Americans each year, according to CDC estimates. Patients are usually treated with anticoagulants, but a recent study found that a subset of patients may benefit from a combination approach of interventional treatment and clot-busting drugs.